Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merisant seeks bankruptcy protection

This article was originally published in The Tan Sheet

Executive Summary

The maker of stevia-based sweetener PureVia reports Jan. 12 that the "recent turmoil in the financial and credit markets has made it impossible" to refinance its debt, thus necessitating its filing for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware. Chicago-based Merisant, which also markets sugar substitute Equal, adds it has secured $20 million in debtor-in-possession financing and will continue normal operations, including advancing "plans to introduce natural sweeteners in other markets," according to CEO Paul Block. Merisant subsidiary Whole Earth Sweetener launched PureVia in December with PepsiCo, which is formulating beverages with the sweetener (1"The Tan Sheet" Dec. 22, 2008, p. 8)

You may also be interested in...

Stevia Products Roll Out As GRAS, But Must Win Over Consumer Sweet Tooth

Stevia-based sweeteners are enjoying a coming out party with FDA giving the go-ahead to Cargill's Truvia and Merisant's PureVia

Big Pharma BD Execs Tell Start-Ups: Don’t Be Afraid To Ask Us For Help

Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.

Transformation Into Viatris Not Seen As The Solution Mylan Needs

Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts